ZYME Stock: Price, Earnings History and SEC Filings
Zymeworks Inc. (ZYME) last traded at $28.61, down 0.35% on the latest session and up 8.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.62 against an analyst estimate of $-0.56, a miss of 10.7%.
$28.61 -0.35%
1 month+8.00%
52-week high$31.34
52-week low$16.00
Volume2.88M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ZYME earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.62 | $-0.56 | -10.71% |
| Mar 2026 | May 7, 2026 | $-0.59 | $-0.10 | -490.00% |
| Dec 2025 | Mar 2, 2026 | $-0.55 | $-0.35 | -57.14% |
| Sep 2025 | Nov 6, 2025 | $-0.26 | $-0.30 | +13.33% |
ZYME beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ZYME
SEC filing data is not available right now. You can search for ZYME on SEC EDGAR.
ZYME news
- Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal UpsideOct 27, 2026 · marketbeat.com
- Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of DirectorsOct 27, 2026 · finance.yahoo.com
- How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing DealOct 26, 2026 · finance.yahoo.com
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsOct 26, 2026 · biopharmadive.com
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026Oct 24, 2026 · finance.yahoo.com
- Zymeworks Announces Global DLL3 T-Cell Engager PartnershipOct 24, 2026 · theglobeandmail.com
- Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This WeekOct 24, 2026 · stocktwits.com
About Zymeworks Inc.
Zymeworks Inc. (ZYME) is a US-listed public company on Nasdaq.